Abstract 46P
Background
The mechanism of PD-1 inhibitors-induced myocarditis in individuals with tumor is still unclear. Regulatory T cells (Treg) can directly inhibit T cell proliferation and activation, and also produce inhibitory cytokines with potent immunosuppressive properties. Deletion or aberrant function of Treg usually leads to autoimmune diseases. But reports on the role of Treg in PD-1 inhibitor-associated myocarditis are still very limited, and its role in the pathogenesis of myocarditis needs to be further explored. In addition, alterations in the composition of the gut microbiota and its metabolites have been shown to be involved in the development of several cardiovascular and autoimmune diseases.
Methods
We first established a melanoma model in mice, which were subsequently divided into three groups: control group, Anti-PD1 group and fecal microbiota removal (FMR) group. The control group and Anti-PD1 group were subcutaneously injected with mouse IgG and PD-1 inhibitors respectively, and FMR group were injected with PD-1 inhibitors subcutaneously along with oral antibiotic antimicrobials to clear the intestinal microbiota. Afterwards, we assessed the severity of myocarditis in mice, performed flow cytometry analysis of immune cells in the heart, determined transcript levels of Treg-related cytokines in the heart, and performed 16S rRNA gene sequence analysis of gut microbiota and correlation analysis of enriched gut microbiota with myocarditis factors.
Results
PD-1 inhibitors induced myocarditis in melanoma mice, leading to a reduction in intracardiac Tregs and downregulation of inflammatory suppressor transcript levels, as well as altering the gut microbial composition of the mice. However, in the presence of gut microbial removal, myocarditis manifestations in the mice described above were attenuated. In addition, microbes enriched in the gut of mice after treatment with PD-1 inhibitors showed a strong correlation with factors associated with the development of myocarditis.
Conclusions
PD-1 inhibitors induced myocarditis and significant reduction of intracardiac Treg in melanoma mice. It is highly likely that alterations in the composition of the gut microbiota due to PD-1 inhibitors played a key role in this process.
Legal entity responsible for the study
The authors.
Funding
Shanxi Provincial Health Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract